Cabozantinib (C) in combination with atezolizumab (A) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of expanded cohort 6 of the COSMIC-021 study
Publication/Presentation Date
9-2021
Volume
32
Issue
5
First Page
1299
Last Page
1300
Published In/Presented At
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
Department(s)
Administration and Leadership
Document Type
Article
COinS